INCY · 8-K · 20261029PR000063
Acquisition / Partnership / Divestiture
INCYTE CORP · 2026-10-29 · Importance 71 · Surprise 60 · Contradicted
Incyte completed its acquisition of Vega Therapeutics in July 2026 for $1.25 billion, acquiring all outstanding shares. Vega added latarcibart, an investigational monoclonal antibody in Phase 3 development for von Willebrand disease, to Incyte’s pipeline. Star Therapeutics is eligible for up to $750 million in additional payments upon achievement of sales milestones. The acquisition generated a $1.23 billion upfront IPR&D expense in the third quarter, materially affecting reported R&D and operating results.
Key facts
- Incyte completed its acquisition of Vega Therapeutics in July 2026 for $1.25 billion; Star Therapeutics is eligible for up to $750 million in additional sales-milestone payments. source
- The Vega Therapeutics acquisition added latarcibart, a Phase 3 investigational monoclonal antibody for von Willebrand disease, to Incyte’s late-stage pipeline. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | realized | — | Incyte completed its acquisition of Vega Therapeutics in July 2026 for $1.25 billion; Star Therapeutics is eligible for up to $750 million… |
| liability | negative | contingent | — | Incyte completed its acquisition of Vega Therapeutics in July 2026 for $1.25 billion; Star Therapeutics is eligible for up to $750 million… |